Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veterinary rotavirus RNA particle vaccine
- Development stage
- Preclinical
- Lead developer
- Merck Animal Health
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The veterinary rotavirus RNA particle vaccine is a biological product developed by AlphaVax in partnership with Merck Animal Health (Intervet) for the prevention of rotavirus infection in livestock, particularly swine. The vaccine utilizes AlphaVax's proprietary alphavirus-based RNA particle (replicon particle) technology, specifically the Venezuelan equine encephalitis virus (VEEV) replicon system. In this platform, the antigen-encoding RNA is packaged into propagation-defective RNA particles that deliver the genetic material directly to host cells. This process triggers robust humoral and cellular immune responses against the rotavirus antigen without the requirement for a live pathogen or traditional adjuvants.
- Other names
- Rotavirus veterinary RNA particle vaccineAlphaVax rotavirus vaccinealphavaccine rotavirus vaccineVRP rotavirus vaccine
02
Targets
VP6 (Rotavirus capsid protein VP6)
Beyond the preview
Go deeper on veterinary rotavirus RNA particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veterinary rotavirus RNA particle vaccine.